Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 5, 2021

View Archived Issues

Qurient initiates phase II study of telacebec in moderate COVID-19

Enrollment opens in phase I study of LP-168 in relapsed or refractory B-cell malignancies

RGS10 gene mutations linked to combined immunodeficiency

Allergy Therapeutics reports findings from ex vivo biomarker study of VLP Peanut

FDA clears IND for [225Ac]PSMA I&T for mCRPC

PanTher receives ethics approval to initiate phase I study of PTM-101 in Australia

Merck & Co. identifies new arginase inhibitors

New MAP2K inhibitors discovered at Immuneering Corp.

GB-5001 demonstrates safety in toxicity study in dogs

The University of Washington and the Department of Veterans Affairs patent glycolysis inhibitors

New cyclophilin ligands described by Harvard College

Exosomes conjugated to VEGF antibodies show efficacy in models of choroidal neovascularization

Target engagement, safety seen with anti-TREM-2 monoclonal antibody AL-002 in healthy subjects

GWAS gives clues to menopause, and healthy aging

89Zr-Immuno-PET using bispecific Abeta MAb as promising diagnostic strategy for Alzheimer's disease

Updated results provided for ACI-24 in adults with Down syndrome

Telix initiates first-in-human study of next-generation prostate cancer therapy candidate TLX-592

Noema studies PDE10A inhibitor NOE-105 for Tourette's syndrome in phase IIa

KIR3DL3-HHLA2 pathway could be targeted for cancer immunotherapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.